Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822352 | 0.92 | EBP (0.48) | NPY5RSIGMAR1EBPCYP19A1CYP17A1 | |
| SCHEMBL6822421 | 0.83 | CYP19A1 (0.50) | NPY5RMAOBSIGMAR1CYP19A1CYP17A1 | |
| SCHEMBL6825388 | 0.81 | CYP19A1 (0.39) | NPY5RSIGMAR1CYP19A1CYP17A1ALDH1A1 | |
| SCHEMBL6825819 | 0.78 | NPC1 (0.36) | SIGMAR1CYP19A1NPC1RAB9A | |
| SCHEMBL6822297 | 0.78 | CYP19A1 (0.43) | SIGMAR1EBPCYP19A1CYP17A1ACHE | |
| SCHEMBL6825052 | 0.77 | CYP19A1 (0.61) | CYP19A1CYP17A1NPC1ALDH1A1LMNA | |
| SCHEMBL6825247 | 0.75 | CYP19A1 (0.46) | CYP19A1CYP17A1NPC1ALDH1A1LMNA | |
| SCHEMBL6825366 | 0.73 | TYMS (0.41) | CYP19A1CYP17A1ALDH1A1LMNARAB9A | |
| SCHEMBL6825253 | 0.73 | CYP19A1 (0.44) | CYP19A1CYP17A1NPC1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL6825962 | 0.73 | TYMS (0.40) | CYP19A1CYP17A1ALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028110-B1 | NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | DAIICHI SEIYAKU CO (JP) | 2004-04-14 | — | — | EP | claimed |
| EP-1028110-B1 | NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | DAIICHI SEIYAKU CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-6559157-B2 | Excellent 17 alpha - hydroxylase/C17-20-lyase and aromatase inhibiting activity, thromboxan A2 synthesis inhibiting activity, useful as preventive and/or therapeutic agents for various male and female sex hormone dependent diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-06 | — | — | US | disclosed |
| US-20020032211-A1 | Novel dihydronaphthalene compounds and processes of producing the same | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-1028110-A1 | NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME | Yukijirushi Nyugyo Kabushiki Kaisha (JP) | 2000-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032211-A1 | Novel dihydronaphthalene compounds and processes of producing the same | CYP19A1, HSD17B11, CYP17A1 | NPY5R 2446/4885MAOB 134/4885SIGMAR1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.